Prostate Adenocarcinoma Clinical Trials in Chicago, Illinois

10 studies are recruiting for prostate adenocarcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

   This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   413 in total

   Run by

   NRG Oncology

   See if you can join NCT05946213 on ClinicalTrials.gov

2. MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

   Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT05710380 on ClinicalTrials.gov

3. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

   Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   4 in total

   Run by

   University of Chicago

   See if you can join NCT05726292 on ClinicalTrials.gov

4. Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

   This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg dai…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   5 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06022822 on ClinicalTrials.gov

5. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

   This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   341 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT04423211 on ClinicalTrials.gov

6. Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

   The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

   Stage

   Phase 1

   Ages

   21 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   10 in total

   Run by

   Alessa Therapeutics Inc.

   See if you can join NCT06257693 on ClinicalTrials.gov

7. rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

   This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Northwestern University

   See if you can join NCT05852041 on ClinicalTrials.gov

8. An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

   This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following prior treatment (biochemical recurrence) but who were prostate specifi…

   Stage

   EARLY_Phase 1

   Ages

   Any age

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Northwestern University

   See if you can join NCT06813898 on ClinicalTrials.gov

9. Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

   This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Sean Sachdev

   See if you can join NCT06499870 on ClinicalTrials.gov

10. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov